Acquisition Pending
Chemomab Therapeutics Ltd. reverse merger with Scipher Medicine Corporation: what happens to stock options and RSUs
Chemomab is combining with privately held Scipher Medicine in a reverse merger, so Scipher's business continues as the public company. Existing Chemomab holders, and holders of vested options, get one contingent value right (CVR) per share tied to the legacy business. This is not a cash buyout; the shareholder meeting is December 4, 2026.
- Deal
- Reverse merger with Scipher Medicine Corporation
- What holders receive
- reverse merger; existing holders receive contingent value rights (CVRs)
- Agreement signed
- July 7, 2026
- Shareholder vote
- December 4, 2026
- Expected closing
- Fourth calendar quarter of 2026
How equity awards are treated
The filing's equity award section could not be summarized reliably. Read the source filing below.
What this means for your taxes
- ESPP shares sold in the deal within 2 years of the offering date or 1 year of purchase are a disqualifying disposition: part of the gain is taxed as ordinary income.
- Timing: expected closing is fourth calendar quarter of 2026. If it could fall either side of December 31, the payout lands in a different tax year, which can matter for estimated payments and for bunching deductions.
General rules, not advice for your situation. Your award agreement and the merger agreement control. Full guide: stock options and RSUs in an acquisition →
Get updates on the Chemomab Therapeutics Ltd. deal
We'll email you when shareholders vote, when the deal closes, and if terms change.
One email per alert. Unsubscribe any time. We never sell your address.
Holding a large position in one stock?
Get our checklist of the ways people diversify a concentrated position (staged sales under a 10b5-1 plan, exchange funds, collars, gifting appreciated shares) and the tax trade-off of each. One email, plus alerts for this company.
One email per alert. Unsubscribe any time. We never sell your address.
Source
From the company's SEC filing: DEFM14A (accession 0001493152-26-049444). Last checked against the filing on November 19, 2026. Found an error? Corrections are made the same day; see how we check.
Questions
What will Chemomab Therapeutics Ltd. shareholders receive?
Under the merger agreement, holders receive reverse merger; existing holders receive contingent value rights (CVRs).
What happens to Chemomab Therapeutics Ltd. stock options and RSUs?
See the treatment of equity awards section in the source filing.
When will the deal close?
The filing expects closing fourth calendar quarter of 2026.